#United States #Dynavax Technologies #Emeryville #HEPLISAV-B #CpG 1018

Dynavax at the 2025 Wells Fargo Healthcare Conference

Dynavax Technologies Corporation, a prominent player in the biopharmaceutical sector specializing in vaccine development, has announced its participation in the highly anticipated 2025 Wells Fargo Healthcare Conference. This year, the event will take place on September 3 at 4:30 PM ET and promises to be a platform for unveiling advancements in their innovative vaccine solutions.

As a commercial-stage company listed on Nasdaq under the ticker DVAX, Dynavax focuses on creating and commercializing vaccines that address urgent public health needs. With their approach tailored to combat infectious diseases, they bring two major products to market: HEPLISAV-B, an adjuvanted hepatitis B vaccine, and CpG 1018, an adjuvant that enhances vaccine efficacy. Both products are pivotal in the fight against diseases and demonstrate the company's commitment to public health.

Event Access and Overview

The Wells Fargo Healthcare Conference is renowned for featuring industry leaders who share insights into the latest developments in healthcare and biopharmaceuticals. Dynavax has confirmed that the fireside chat will be accessible via a webcast, allowing interested parties to engage from anywhere. The webcast will be available on the Events & Presentations section of Dynavax's investor website, ensuring that stakeholders can stay informed about the company's progress and future endeavors.

HEPLISAV-B has been approved in several major markets, including the United States, the European Union, and the United Kingdom, showcasing its global reach and acceptance. It is designed to prevent hepatitis B infections across all known virus subtypes in adults aged 18 and above. The vaccine's innovative formulation utilizes CpG 1018, illustrating Dynavax's cutting-edge approach to immunology.

A Vision for Public Health

Dynavax's commitment extends beyond just their current offerings. The company is actively engaged in research and development of new vaccines, aiming to address emerging healthcare challenges. Their innovative approach is essential not only for preventive care but also for enhancing overall public health outcomes. With a strong pipeline of developmental products, Dynavax is setting the standard for future vaccine technologies.

As the healthcare landscape continues to evolve, the upcoming appearance at the Wells Fargo Conference reveals Dynavax's proactive stance in sharing knowledge and advancements that can benefit the wider community. The company is not merely focused on product commercialization; it emphasizes education, partnership, and collaboration in the biotech realm.

Looking Ahead

In anticipation of the conference, Dynavax reiterates its dedication to pushing the boundaries of vaccine technology and maintaining transparency with investors and the public. The 2025 Wells Fargo Healthcare Conference represents more than just a corporate event for Dynavax; it is an opportunity to connect with peers, showcase their advancements, and reaffirm their mission to protect global populations from infectious diseases.

For those interested in accessing the live webcast or learning more about Dynavax's product portfolio and ongoing projects, further information can be found by visiting Dynavax's official website at www.dynavax.com. This provides a gateway to understanding how Dynavax is shaping the future of immunization and public health.

Through events like this, Dynavax remains committed to enhancing global health through innovative science and effective vaccine solutions. As they prepare to take the stage, the company looks forward to engaging discussions that could influence healthcare practices and policies worldwide.